Andre Watson is a young and ambitious CEO, entrepreneur, and bioengineering innovator who founded and leads Ligandal, a cutting-edge company that specializes in using nanotechnology to create personalized therapies and vaccines. With an educational background in Biomedical Engineering, focused on Biomaterials Science and gene delivery, Andre's passion is the creation of targeted, customized, and ultra-rapid therapies and vaccines for pandemics and outbreaks.
At Ligandal, Andre is focused on developing peptide-based cures for the COVID-19 pandemic using a peptide nanoscaffold approach combined with antidote-vaccine that can be tailored to various cell targeting and gene therapy needs. Andre's expertise lies in targeted gene delivery, nano- and biomaterials, computational modeling of peptides, binding simulations, immunoengineering, as well as CRISPR and TALEN based gene editing. Under his leadership, Ligandal has shown remarkable progress in developing peptide-based delivery of CRISPR, RNA, DNA, siRNA, and a range of genes or proteins to any cell type.
Andre's passion for personalized medicine and biomaterials is driven by his desire to create a world where biological systems can be programmed and controlled to bring about humanity's prosperity. Along with his professional pursuits, Andre also indulges in his love for music, playing the piano, and exploring the world through food.